WuXi Biologics completes construction of Asia’s largest perfusion biologics manufacturing facility using disposable bioreactors
Sep 22, 2016
SHANGHAI, Sep. 22, 2016 -- WuXi Biologics, a leading open-access R&D capability and technology platform company dedicated to biologics and a WuXi AppTec company, announced today the opening of a new commercial-scale cGMP biologics perfusion manufacturing facility in Wuxi city, China.
In April 2015 WuXi Biologics announced plans to build a $150 million commercial biologics manufacturing facility in Wuxi city. The first phase of construction is complete and commences operation today after 17 months. The new facility accommodates two 1000L disposable bioreactors for perfusion processes and is the largest perfusion biologics manufacturing facility to date in Asia implementing disposable bioreactors.
This added capacity will support WuXi's robust biologics commercial manufacturing pipeline and enable WuXi to maintain its position as the premier biologics manufacturer in China as well as a leader worldwide. The new commercial biologics manufacturing facility will also address the needs of Chinese companies as Marketing Authorization Holder (MAH) system is currently being piloted.
"The opening of the new commercial manufacturing facility marks another milestone for WuXi," said Dr. Ge Li, Chairman and CEO of WuXi AppTec, "we will uphold the highest quality standards to expedite global development of biologics for both international and domestic clients."
“This new facility further strengthens WuXi Biologics' capabilities in integrated biologics discovery, development, and manufacturing services,” said Dr. Chris Chen, CEO of WuXi Biologics, “WuXi Biologics is committed to providing a seamless, truly ONE-stop service for our partners and clients from concept to commercialization. ”
About WuXi AppTec
WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities in small molecule R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics, WuXi platform is enabling more than 2,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi’s dream that “every drug can be made and every disease can be treated.” Please visit http://www.wuxiapptec.com
About WuXi Biologics
WuXi Biologics, a WuXi AppTec company, is a leading open-access technology capability and technology platform to enable anyone and any company to develop biologics. As a premier Contract Discovery, Development and Manufacturing Organization (CDMO), WuXi Biologics provides our worldwide clients with the necessary expertise, quality and capacities to develop biologic drugs from concept to commercialization. Along with our WuXi AppTec affiliates, we provide the world with the ONE true single-source approach that saves our clients critical time and money. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi’s Biologics services, please visit: http://www.wuxibiologics.com.
For more information, please contact:
Director of Corporate Communications
Ms. Jia Li
Senior Manager of Corporate Communications